Table 1.
Expression of IL-27 in inflammatory autoimmune diseases.
| Disease | Sample | Expression | Treatment | Ethnicity | Reference |
|---|---|---|---|---|---|
| SLE | Serum | Reduced a | Steroids, Antimalarial agents, Azathioprine, Micophenolate mofetil, Thalidomide | Brazilian | (119) |
| Serum | Reduced a | Corticosteroid | Southern Chinese | (120) | |
| Serum, urine | Increased a | None | Northern Chinese | (121) | |
| PBMC | Increased a | None | North American | (122) | |
| RA | Plasmablast, serum, Breg cell | Increased a | None | Northern Chinese | (123) |
| Serum | Increased a | None | Southern Chinese, Northern Chinese | (124, 125) | |
| Plasma | Increased a | None | Southern Chinese | (126) | |
| Synovium, synovial fluid | Increased a | None | Japanese | (127) | |
| Synovitis | Reduced a | Methotrexate | UK | (128) | |
| SS | Serum | Increased a | Unknown | Northern Chinese | (129) |
| Serum, salivary glands | Increased a | Unknown | UK | (130) | |
| PBMC, serum | Reduced a | Prednisone, Hydroxychloroquine, Cyclophosphamine, Leflunomide | Southern Chinese | (131) | |
| Serum | Reduced b | None | – | (131) | |
| Plasma | Reduced a | Unknown | Northern Chinese | (132) | |
| BD | Serum | Reduced a | Unknown | Turkish | (133) |
| Serum, PBMC | Reduced a | None | Southern Chinese | (134) | |
| Serum | Increased a | Prednisone | Southern Chinese | (135) | |
| Serum | Increased a | None | Iranian | (136) | |
| IBD | PBMC | Normal a | 5-aminosalicylic acid, Prednisone, Azathioprine (AZA), Infliximab | Iranian | (137) |
| Colonic biopsy | Increased a | Mesalazine, Azathioprine, Prednisone, Mercaptopurine | Mexican | (138) | |
| Colonic mucosa | Increased a | Steroids, Azathioprine | German | (139) | |
| Intestinal mucosa | Increased a | Mesalazine, Corticosteroids, Methotrexate, Azathioprine | German | (140) | |
| Serum, stool, moDC | Increased a | Unknown | Southern Chinese | (141) | |
| Serum, cecum | Increased b | None | – | (141) | |
| MS | Serum | Reduced a | None | Romanian, Northern Chinese, Iranian | (142–144) |
| Serum, cerebrospinal fluid | Increased a | Corticoids | Swiss | (145) | |
| Plasma | Increased a | INFβ | Iranian | (146) | |
| Serum, cerebrospinal fluid | Increased a | Unknown | Canadian | (147) | |
| Serum | Increased b | Unknown | – | (148) | |
| Brain tissue | Increased a | Unknown | Canadian | (149) | |
| Psoriasis | Serum | Increased a | None | Brazilian | (150) |
| Serum | Increased a | Steroids, Vitamin D3 | Japanese | (151) | |
| Serum, epidermis, dermis, PBMC | Reduced a | None | Southern Chinese | (152) | |
| SSc | Serum, B cell, CD4+ T cell | Increased a | None | Japanese | (153) |
| T1D | Serum | Normal a | None | Polish | (154) |
| Serum | Reduced a | Insulin | Iranian | (155) | |
| Plasma | Increased a | Insulin | Estonian | (156) | |
| Treg cell | Reduced a | Insulin | Polish | (157) | |
| VKH | Serum, PBMC | Reduced a | None | Southern Chinese | (158) |
| Serum | Increased a | None | Southern Chinese | (159) | |
| AS | Serum, synovial fluid | Increased a | Unknown | Northern Chinese | (160) |
SLE, systemic lupus erythematosus; RA, rheumatoid arthritis; SS, Sjogren syndrome; BD, Behcet’s disease; IBD, inflammatory bowel disease; MS, multiple sclerosis; SSc, systemic sclerosis; T1D, type 1 diabetes; VKH, Vogt–Koyanagi–Harada; AS, ankylosing spondylitis; PBMC, peripheral blood mononuclear cells; Breg cell, regulatory B cell; moDC, monocyte-induced dendritic cell; Treg cell, regulatory T cell.
Human.
Mice.